Miravitlles Marc, Llor Carles, Naberan Karlos, Cots Josep María, Molina Jesús
Pneumology Department, Institut Clínic del Tòrax (IDIBAPS), Red Respira FIS-ISCIII-RTIC-03/11, Hospital Clínic, Villarroel 170, 08036 Barcelona, Catalonia, Spain.
Respir Med. 2005 Aug;99(8):955-65. doi: 10.1016/j.rmed.2005.01.013.
To identify risk factors for late recovery and failure after ambulatory treatment of exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD).
Observational, non-randomised study of risk factors carried out in 2001 and 2002 in Primary Care practices. Patients aged 40 or older diagnosed with an exacerbation of CB or COPD of probable bacterial etiology were included in the study and followed up for 10 days. Patients were treated with amoxicillin plus clavulanic acid (co-amoxiclav) 500-125 mg tds for 10 days, clarithromycin 500 mg bd for 10 days or moxifloxacin 400 mg od for 5 days.
Two hundred and fifty-two general practitioners participated, registering 1147 valid patients. The rate of failure at day 10 was 15.1% without significant differences among the antibiotic treatments. Median time to recovery was 5 days. Factors significantly associated with late recovery (>5 days) on multivariate analysis were: use of long-term oxygen (OR=1.96; 95%CI=1.35-2.85); use of short-acting beta-2 agonists (OR=1.51; 1.17-1.92). The use of moxifloxacin had a "protective" effect against late recovery compared to co-amoxiclav (OR=0.34; 0.26-0.45) and clarithromycin (OR=0.41; 0.31-2.85). Factors associated with therapeutic failure were: previous hospitalisation (OR=1.61; 1.08-2.42); and 2 or more exacerbations the previous year (OR=1.51; 1.04-2.17); criteria of CB had a protective effect against failure (OR=0.53; 0.35-0.79).
There are readily identifiable risk factors for ambulatory treatment failure of exacerbations of CB and COPD. In addition, long-term oxygen therapy and short-acting beta-2 agonists are associated with late recovery, and the use of moxifloxacin compared with co-amoxiclav and clarithromycin is associated with faster recovery of symptoms.
确定慢性支气管炎(CB)和慢性阻塞性肺疾病(COPD)急性加重期门诊治疗后恢复延迟和治疗失败的危险因素。
2001年和2002年在基层医疗实践中开展的关于危险因素的观察性、非随机研究。纳入年龄40岁及以上、诊断为可能由细菌病因引起的CB或COPD急性加重期的患者,并随访10天。患者接受阿莫西林加克拉维酸(阿莫西林克拉维酸钾)500 - 125毫克每日三次,共10天;克拉霉素500毫克每日两次,共10天;或莫西沙星400毫克每日一次,共5天的治疗。
252名全科医生参与,登记了1147例有效患者。第10天的治疗失败率为15.1%,抗生素治疗之间无显著差异。恢复的中位时间为5天。多因素分析中与恢复延迟(>5天)显著相关的因素为:长期吸氧(比值比[OR]=1.96;95%置信区间[CI]=1.35 - 2.85);使用短效β-2激动剂(OR=1.51;1.17 - 1.92)。与阿莫西林克拉维酸钾相比,莫西沙星的使用对恢复延迟有“保护”作用(OR=0.34;CI=0.26 - 0.45),与克拉霉素相比也有此作用(OR=0.41;CI=0.31 - 2.85)。与治疗失败相关的因素为:既往住院史(OR=1.61;CI=1.08 - 2.42);以及前一年有2次或更多次急性加重(OR=1.51;CI=1.04 - 2.17);CB标准对治疗失败有保护作用(OR=0.53;CI=0.35 - 0.79)。
CB和COPD急性加重期门诊治疗失败有易于识别的危险因素。此外,长期氧疗和短效β-2激动剂与恢复延迟有关,与阿莫西林克拉维酸钾和克拉霉素相比,莫西沙星的使用与症状更快恢复有关。